TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Hassel, J. C. AU - Heinzerling, L. AU - Aberle, J. AU - Bähr, O. AU - Eigentler, T. K. AU - Grimm, M. -. O. PY - 2017 DA - 2017// TI - Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions JO - Cancer Treat Rev VL - 57 UR - https://doi.org/10.1016/j.ctrv.2017.05.003 DO - 10.1016/j.ctrv.2017.05.003 ID - Hassel2017 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Cooling, L. L. AU - Sherbeck, J. AU - Mowers, J. C. AU - Hugan, S. L. PY - 2017 DA - 2017// TI - Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation JO - Immunohematology VL - 33 ID - Cooling2017 ER - TY - JOUR AU - Hodi, F. S. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined nivolumab and ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Ahmad, S. AU - Lewis, M. AU - Corrie, P. AU - Iddawela, M. PY - 2012 DA - 2012// TI - Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma JO - J Oncol Pharm Pract VL - 18 UR - https://doi.org/10.1177/1078155211411001 DO - 10.1177/1078155211411001 ID - Ahmad2012 ER - TY - JOUR AU - Helgadottir, H. AU - Kis, L. AU - Ljungman, P. AU - Larkin, J. AU - Kefford, R. AU - Ascierto, P. A. PY - 2017 DA - 2017// TI - Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx177 DO - 10.1093/annonc/mdx177 ID - Helgadottir2017 ER - TY - JOUR AU - Comito, R. R. AU - Badu, L. A. AU - Forcello, N. PY - 2017 DA - 2017// TI - Nivolumab-induced aplastic anemia: a case report and literature review JO - J Oncol Pharm Pract VL - 34 ID - Comito2017 ER - TY - JOUR AU - Nakao, S. AU - Feng, X. AU - Sugimori, C. PY - 2005 DA - 2005// TI - Immune pathophysiology of aplastic anemia JO - Int J Hematol VL - 82 UR - https://doi.org/10.1532/IJH97.05116 DO - 10.1532/IJH97.05116 ID - Nakao2005 ER - TY - JOUR AU - Xiao, Y. AU - Zhao, S. AU - Li, B. PY - 2017 DA - 2017// TI - Aplastic anemia is related to alterations in T cell receptor signaling JO - Stem Cell Investig VL - 4 UR - https://doi.org/10.21037/sci.2017.09.07 DO - 10.21037/sci.2017.09.07 ID - Xiao2017 ER - TY - JOUR AU - Ford, E. S. AU - Cogswell, M. E. PY - 1999 DA - 1999// TI - Diabetes and serum ferritin concentration among U.S. adults JO - Diabetes Care VL - 22 UR - https://doi.org/10.2337/diacare.22.12.1978 DO - 10.2337/diacare.22.12.1978 ID - Ford1999 ER - TY - JOUR AU - Michot, J. M. AU - Bigenwald, C. AU - Champiat, S. AU - Collins, M. AU - Carbonnel, F. AU - Postel-Vinay, S. PY - 2016 DA - 2016// TI - Immune-related adverse events with immune checkpoint blockade: a comprehensive review JO - Eur J Cancer VL - 54 UR - https://doi.org/10.1016/j.ejca.2015.11.016 DO - 10.1016/j.ejca.2015.11.016 ID - Michot2016 ER - TY - JOUR AU - Du, X. AU - Tang, F. AU - Liu, M. AU - Su, J. AU - Zhang, Y. AU - Wu, W. PY - 2018 DA - 2018// TI - A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy JO - Cell Res VL - 90 ID - Du2018 ER - TY - JOUR AU - Du, X. AU - Liu, M. AU - Su, J. AU - Zhang, P. AU - Tang, F. AU - Ye, P. PY - 2018 DA - 2018// TI - Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice JO - Cell Res VL - 271 ID - Du2018 ER -